Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.
Cerebrolysin is NOT a single molecule, it is a porcine-brain-derived mixture of low-molecular-weight peptides (<10 kDa, ~25% peptides by nitrogen content) plus free amino acids, given IV/IM. A single half-life does not meaningfully apply. The commonly-repeated '3-4 h half-life' is a vendor figure and could NOT be traced to a primary PK study; flagged unverified. Clinical trials note functional benefit persists to day 90 long after plasma clearance, consistent with a trophic (not classical-PK) effect.
Dosed as milliliters of solution (typically 10-30 mL IV daily in stroke trials such as CARS), NOT in micrograms of a defined active, so mcg low/high are not applicable. See trial sources for mL regimens.
Large but heterogeneous RCT base for acute ischemic stroke and vascular dementia; meta-analyses (e.g. 14-RCT pooled analysis) suggest benefit in more severe/early stroke but effect sizes are modest and some trials are industry-sponsored. A Cochrane-type view has flagged risk of bias. Mixed, not definitive.
Reconstituted: Supplied as a sterile aqueous ampoule/solution; store per manufacturer label (protect from light). Not a lyophilized research powder.
Porcine-derived biological, theoretical immunogenicity/allergy risk. Given parenterally in medical settings. Composition is not fully chemically defined; batch variability possible.